The Bank of England said more companies are triggering plans for a no-deal Brexit as it kept policy in a holding pattern while the government takes withdrawal talks to the brink.
Pound investors are ripping up their Brexit playbooks as the chance of a no-deal exit flares once again.
Biogen Inc. and partner Eisai Co. Ltd. said that they had decided to halt a late-stage study of an experimental Alzheimer’s disease drug, marking another setback for drugmakers’ efforts to find a therapy for the degenerative ailment.
Biogen Inc. and partner Eisai Co’s decision to stop late-stage studies of their Alzheimer’s disease drug aducanumab could wipe out about 30 percent of the drugmaker’s value, according to Mizuho analyst Salim Syed.
New research shows that real estate is both a better and safer investment than previously believed.
{{ video.ContentPackages[0].ScheduleStartDateTime | fromNow }}
{{ currentStream.Desc }}